LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Home・Akcijų sąrašas・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

34.23 -3.06

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

34.23

Max

34.23

Pagrindiniai rodikliai
By Trading Economics
Pajamos	11M 51M
Pardavimai	39M 239M
P/E Sektoriaus vid.	11.36 110.024
Pelnas, tenkantis vienai akcijai	1.08
Pelno marža	21.242
Darbuotojai	268
EBITDA	14M 73M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+40.3% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-24

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	387M 2.1B
Ankstesnė atidarymo kaina	37.29
Ankstesnė uždarymo kaina	34.23

Naujienos nuotaikos

By Acuity

53%

47%

289 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

29.8 / N/A Palaikymas ir pasipriešinimas

Harmony Biosciences Holdings Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-19 23:47; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-02-19 23:47; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Caution Over Potential U.S. Strike on Iran -- Market Talk

2026-02-19 23:39; UTC

Įsigijimai, susijungimai, perėmimai

Swiss Re Corporate Solutions to Buy QBE Insurance's Global Trade Credit and Surety Business >SREN.EB

2026-02-19 23:38; UTC

Uždarbis

Samsung Fire & Marine Insurance 2025 Net KRW2.020T Vs. Net KRW2.077T >000810.SE

2026-02-19 23:38; UTC

Uždarbis

Samsung Fire & Marine Insurance 2025 Oper Pft KRW2.659T Vs. Pft KRW2.650T >000810.SE

2026-02-19 23:38; UTC

Uždarbis

Samsung Fire & Marine Insurance 2025 Rev KRW24.779T Vs. KRW22.657T >000810.SE

2026-02-19 23:37; UTC

Rinkos pokalbiai

Gold Edges Lower on Possible Position Adjustment -- Market Talk

2026-02-19 23:34; UTC

Uždarbis

Samsung Fire & Marine Insurance 4Q Net Profit Missed FactSet-Compiled Consensus

2026-02-19 23:34; UTC

Uždarbis

Samsung Fire & Marine Insurance 4Q Net KRW234.38B Vs. Net KRW207.88B >000810.SE

2026-02-19 23:33; UTC

Uždarbis

Samsung Fire & Marine Insurance 4Q Oper Pft KRW391.26B Vs. Pft KRW252.81B >000810.SE

2026-02-19 23:33; UTC

Uždarbis

Samsung Fire & Marine Insurance 4Q Rev KRW6.083T Vs. KRW6.297T >000810.SE

2026-02-19 22:13; UTC

Rinkos pokalbiai

Goodman's Lack of Earnings Upgrade 'Largely Timing Related' -- Market Talk

2026-02-19 22:08; UTC

Uždarbis

Fairfax Financial 4Q Rev $8.11B >FFH.T

2026-02-19 22:07; UTC

Uždarbis

Eldorado Gold 4Q EPS $1.19 >ELD.T

2026-02-19 22:06; UTC

Uždarbis

Centerra Gold: 2026 Consolidated Gold Production Expected 250,000 to 280,000 Ounces, Copper Production Expected 50M to 60M Pounds >CG.T

2026-02-19 22:05; UTC

Uždarbis

Eldorado Gold 4Q Adj EPS 63c >ELD.T

2026-02-19 22:05; UTC

Uždarbis

Eldorado Gold 4Q Rev $577.2M >ELD.T

2026-02-19 22:04; UTC

Uždarbis

Eldorado Gold 4Q Gold Sales 126,923 Ounces >ELD.T

2026-02-19 22:04; UTC

Uždarbis

Eldorado Gold 4Q Gold Production 123,416 Ounces >ELD.T

2026-02-19 21:50; UTC

Rinkos pokalbiai

Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2026-02-19 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-19 21:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-02-19 21:43; UTC

Uždarbis

St Barbara 1H Underlying Profit A$1.3 Million Vs A$48.1 Million Loss Year Earlier

2026-02-19 21:42; UTC

Įsigijimai, susijungimai, perėmimai

Palo Alto Networks Announces Offer to Purchase Relating to CyberArk Software Ltd.'s 0.00% Convertible Senior Notes Due 2030

2026-02-19 21:42; UTC

Uždarbis

St Barbara 1H Revenue A$128.8 Million, Up 32% On-Year

2026-02-19 21:41; UTC

Uždarbis

Correct: St Barbara 1H Net Loss A$249,000

2026-02-19 21:40; UTC

Uždarbis

St Barbara 1H Net Loss A$249 Million

2026-02-19 21:39; UTC

Uždarbis

Perseus Mining Reaffirms FY26 Production, AISC Guidance

2026-02-19 21:37; UTC

Uždarbis

These Stocks Are Today's Movers: Walmart, Occidental, Klarna, Wayfair, Deere, Omnicom, EPAM, and More -- Barrons.com

2026-02-19 21:37; UTC

Uždarbis

Century Aluminum Expects 1Q Adj EBITDA $215 M to $235 M >CENX

Akcijų palyginimas

Kainos pokytis

Harmony Biosciences Holdings Inc Prognozė

Kainos tikslas

By TipRanks

40.3% į viršų

12 mėnesių prognozė

Vidutinis 48.25 USD 40.3%

Aukščiausias 55 USD

Žemiausias 42 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harmony Biosciences Holdings Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Harmony Biosciences Holdings Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.8 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

289 / 351 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.